Just 18 NHS approvals for unlicensed cannabis medications have been issued since legalisation in November 2018.

Until last week, without a special license, cannabis medications were only prescribed on a private patient basis, costing families thousands of pounds per month.

However, on November 11, one year and ten days after legalisation, it was announced that Epidyolex and Sativex had been approved for prescription on the NHS.

This follows recommendations from the National Institute of Health and Care Excellence (NICE) report released the same day.

NHS prescriptions are now available for patients with MS and intractable epilepsy

104 private prescriptions have been issued: six times as many as the NHS.

However not everyone is pleased with the news.

Leila Simpson, deputy CEO of the United Patients Alliance, a patient advocacy group said:

“Patients have remained frustrated by the slow uptake of prescriptions in both the NHS and private sector.

“We call on the government to urgently increase the speed of access to these vital medicine with uninterrupted supply based on patient need”

MyAccess Clinics in Bristol and London have both received a Care Quality Commission (CQC) licence to issue cannabis medications.

This licence also enables the physicians to provide home care services to those unable to travel.

Clinical director Graham Woodward said:

“We’re delighted to have received our CQC registration, which I’m confident will be a turning point for patients who have so far been unable to access medical cannabis.”

It’s estimated that more than one million Britons use black market cannabis to combat complex health issues.

On this, Graham added:

“I hope this brings renewed hope for the reported 1.4 million people in the UK using ‘street cannabis’ to treat their chronic health conditions that a legitimately sourced, high quality medical cannabis alternative is available.”

Despite NHS prescriptions for Epidyolex and Sativex now being available, many patients and families remain disappointed.

Karen Gray’s seven-year-old son Murray has Myoclonic astatic epilepsy, also known as Doose Syndrome.

Murray initially saw positive effects of the now NHS-approved Epidyolex, but built up a resistance within three months of treatment.

 

Source: i